171 related articles for article (PubMed ID: 31002364)
1. JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type.
Liu J; Liang L; Li D; Nong L; Zheng Y; Huang S; Zhang B; Li T
Oncol Rep; 2019 Jun; 41(6):3219-3232. PubMed ID: 31002364
[TBL] [Abstract][Full Text] [Related]
2. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
3. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation.
Zhang Z; Liang L; Li D; Nong L; Liu J; Qu L; Zheng Y; Zhang B; Li T
Hematol Oncol; 2017 Dec; 35(4):645-654. PubMed ID: 27704586
[TBL] [Abstract][Full Text] [Related]
5. [PRDM1 expression and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type].
Liu JM; Liang L; Huang SS; Li T
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):1010-1016. PubMed ID: 30612403
[No Abstract] [Full Text] [Related]
6. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
9. The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type.
Liang L; Nong L; Zhang S; Zhao J; Ti H; Dong Y; Zhang B; Li T
J Exp Clin Cancer Res; 2014 Jan; 33(1):7. PubMed ID: 24438193
[TBL] [Abstract][Full Text] [Related]
10. Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1.
Baytak E; Gong Q; Akman B; Yuan H; Chan WC; Küçük C
Tumour Biol; 2017 May; 39(5):1010428317701648. PubMed ID: 28468592
[TBL] [Abstract][Full Text] [Related]
11. WP1066 exhibits antitumor efficacy in nasal‑type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway.
Geng L; Li X; Zhou X; Fang X; Yuan D; Wang X
Oncol Rep; 2016 Nov; 36(5):2868-2874. PubMed ID: 27633398
[TBL] [Abstract][Full Text] [Related]
12. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Willerslev-Olsen A; Krejsgaard T; Lindahl LM; Litvinov IV; Fredholm S; Petersen DL; Nastasi C; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Kilian M; Koralov SB; Odum N
Blood; 2016 Mar; 127(10):1287-96. PubMed ID: 26738536
[TBL] [Abstract][Full Text] [Related]
13. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
[TBL] [Abstract][Full Text] [Related]
14. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.
Kim BH; Min YS; Choi JS; Baeg GH; Kim YS; Shin JW; Kim TY; Ye SK
Exp Mol Med; 2011 May; 43(5):313-21. PubMed ID: 21499010
[TBL] [Abstract][Full Text] [Related]
15. Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.
Dong G; Li Y; Lee L; Liu X; Shi Y; Liu X; Bouska A; Gong Q; Kong L; Wang J; Lou CH; McKeithan TW; Iqbal J; Chan WC
Haematologica; 2021 Sep; 106(9):2427-2438. PubMed ID: 32732362
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
Oncogene; 2003 Aug; 22(35):5399-407. PubMed ID: 12934099
[TBL] [Abstract][Full Text] [Related]
17. Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.
Guo Y; Arakawa F; Miyoshi H; Niino D; Kawano R; Ohshima K
Pathol Int; 2014 Jun; 64(6):263-6. PubMed ID: 24965108
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
Nairismägi M-; Gerritsen ME; Li ZM; Wijaya GC; Chia BKH; Laurensia Y; Lim JQ; Yeoh KW; Yao XS; Pang WL; Bisconte A; Hill RJ; Bradshaw JM; Huang D; Song TLL; Ng CCY; Rajasegaran V; Tang T; Tang QQ; Xia XJ; Kang TB; Teh BT; Lim ST; Ong CK; Tan J
Leukemia; 2018 May; 32(5):1147-1156. PubMed ID: 29434279
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
20. The molecular mechanism of curcumol on inducing cell growth arrest and apoptosis in Jurkat cells, a model of CD4⁺ T cells.
Wang H; Wang Y; Jiang X; Wang Z; Zhong B; Fang Y
Int Immunopharmacol; 2014 Aug; 21(2):375-82. PubMed ID: 24877754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
